The 2026 cartilage replacement market is moving away from "one-size-fits-all" solutions toward a diversified, algorithm-driven approach tailored to specific biological profiles and patient needs. This evolving landscape features a spectrum of technologies, including refined osteochondral allografts, cell-expanded implants, and innovative synthetic scaffolds. As companies such as Arthrex and Vericel maintain dominance, new entrants are poised to expand treatment options across the continuum of care. 

Looking ahead at the trends in cartilage replacement for 2026, one fact is becoming increasingly clear: the quest for the "universal cartilage cure" has been officially abandoned. In its place, a more sophisticated reality has emerged, namely that a diversified approach is important for addressing the many different patient case presentations. 

This downloadable article explores how the 2026 marketplace is not defined by a single winner but by a spectrum of solutions designed to meet patients exactly where they are on the continuum of care, such as:

• Osteochondral Grafts: The Standard for Deep Defects in Young Patients - Advances in OCAs have been highlighted by new designs of graft-shaping instrumentation and graft-processing methods intended to extend cell viability. This will be an area of focus in 2026, as researchers and clinicians aim to ... (read more)  

• Cell Expanded Technologies: Is There Competition on the Horizon? - Vericel remains the undisputed leader (on a revenue basis) in the Cartilage Repair Market, with a 57.8% share in FY25. Buoyed by the successful expansion of its clinical provider network, which ended FY25 with over 900 surgeons trained on MACI Arthro, the company posted ... (read more)

This SmartTRAK interview features a panel of experts discussing the clinical shift in hip preservation toward pre-sutured, "off-the-shelf" allograft solutions.

In this interview, SmartTRAK hosts a distinguished panel featuring Andrew Jimenez, MD (Yale School of Medicine), Winston Gwathmey, MD (University of Virginia), and Kevin Whitten (chief commercial officer, AlloSource) to discuss the clinical realities of modern hip preservation. The conversation highlights the shift from time-consuming autograft preparations to innovative "off-the-shelf" allograft solutions. Specifically, the panel explores the operational and clinical advantages of AceConnex, a pre-prepared fascia lata allograft designed to reduce intra-op time and standardize outcomes in labral reconstruction procedures. Click on the following video to learn more (17:44 min). A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK. It's my pleasure to be joined by Dr. Andrew Jimenez, the assistant professor of orthopedics and rehabilitation at Yale School of Medicine, and Dr. Winston Gwathmey, professor of orthopedic surgery at UVA. We're also joined by Kevin Whitten, chief commercial officer at AlloSource, and tonight we're going to be talking about AceConnex.

Thank you very much for joining us, gentlemen. And feel free to jump in at any time, so whoever wants to start with these questions, and again, feel free to interject and jump in. But the first thing I wanted to do is try to get a sense of exactly what type of clinical procedure we're doing here, or what's the issue that occurs with these patients, where AceConnex comes in and is an excellent solution for these patients.

Dr. Winston Gwathmey: I can get started. Hip arthroscopy is a procedure that addresses injuries of the hip that are soft tissue injuries, labral injuries, femoroacetabular impingement. And we've seen a proliferation of this procedure in the past 20 years or so. And with that, we're learning a lot more and more about how the hip functions. And what we're seeing in 2025 is that sometimes the labrum, the soft tissue gasket ring that fits around the hip joint, is not in a situation that can be repaired or salvaged. And so luckily, we've learned a procedure called a labral reconstruction in which we replace part or all of the labrum with the cadaver graft. And what that does is it provides a lot of labral functions and anatomy in a situation where the labrum is deficient or not repairable.

Dr. Andrew Jimenez: And just to piggyback off that, there's been a real evolution in terms of labral treatment and management. Early days of hip arthroscopy, starting off with just labral debridement and labral excision. As our techniques and our implants became better, we moved onto doing labral repair. And what we invariably came up with was ...

Want to learn more about the shift from time-consuming autograft preparations to innovative "off-the-shelf" allograft solutions? Click the button below to download and read the complete transcript of our roundtable discussion, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

The high costs and complexity involved in manual manufacturing hinder the commercial viability of regenerative cell therapies. Octane Biotherapeutics seeks to remove these barriers by integrating its automated "Cocoon" production system with the well-established Novocart 3D and Novocart Inject platforms. SmartTRAK interviews Dr. Robert Spiro, CEO of Octane Biotherapeutics, to explore the company's strategic acquisition of assets from Aesculap Biologics and TETEC AG, and their plan to make a significant entry into the US Cartilage Repair Market. 

Click on the following video to learn more (09:37 min). A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK, and I'm here with Dr. Robert Spiro, the CEO of Octane Biotherapeutics. Thank you for taking the time, really appreciate it.

Robert Spiro: Good to see you, Dave. Thank you.

Yes, good to see you as well. Tell me a little bit about Octane and the acquisition of Novocart 3D and Novocart Inject by Octane.

RS: Sure. It's a journey. It really started about 2010, '11, when I first started with Aesculap Biologics in this space. And having been in the cartilage regenerative space through several companies, really knowing that the scale-up of any type of manual culture, cell culture system was a big challenge from a commercial standpoint. We have always been looking for ways to automate this process. We started some on our own, but I encountered this technology with Octane, which was back in 2011—started that collaboration to transfer our manual autologous chondrocyte culture process to an automated system. They had already really started on this Cocoon technology, but we started to marry it to the Novocart program that long ago.

The relationship was there, all along, with the divestiture away from B. Braun Aesculap as they restructured all of their portfolio. It was really a natural progression for Octane to step in and acquire the company, not only Aesculap Biologics, but our sister company in Germany, TETEC AG, that developed the same technology. Octane Biotherapeutics is fully global, both German as well as US. And so, the Cocoon technology is an important step for us to commercialize both Novocart 3D and Novocart Inject for a number of reasons, and anyone in the cell culture space understands that scale up, scale out of those kind of manual process is expensive. It's one of the things that drives the cost of these products so high. So, it's been a great collaboration, and the fact that they stepped in through the acquisition just made a lot of sense for everybody.

RS: The hallmark of this is why it's really ideal for autologous cells. It's this ...

Want to learn more about how integrating the automated "Cocoon" cell production system with Novocart 3D and Novocart Inject platforms will disrupt the complexity and costs of the US Cartilage Repair Market? Click the button below to download and read the complete transcript of our interview with Dr. Robert Spiro, CEO of Octane Biotherapeutics, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

TOBI President Michael Khadavi, MD, shares his thoughts on the institute's future, key insights from this year’s conference, and exciting new techniques and technologies in the orthobiologics field.  

Dr. Michael Khadavi, a triple-boarded physician in physical medicine and rehab (PM&R), sports medicine, and ultrasound, and the current president of the Orthobiologic Institute (TOBI), discusses the organization's future plans, including expanding its educational programs, research initiatives and strengthening partnerships with industry in an interview with SmartTRAK. Dr. Khadavi also reviews the use of musculoskeletal ultrasound in orthobiologics and highlights the promising results of intraosseous subchondral injections for joint treatments, citing encouraging data from recent studies. Click on the following video (08:22 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK. It's my pleasure to be joined by the president of TOBI. This is Dr. Michael Khadavi, triple-boarded physician in PM&R, sports and ultrasound. Thank you very much for joining us.

Michael Khadavi, MD: It is an honor.

Thanks a bunch. So, we're just wrapping up with TOBI, fantastic presentations throughout the week. It's been really, really great. What's your take-home message to all the people that couldn't make it? What are the things that you learned from these last two days? What's the summary of what you learned here?

MK: This was a strong conference, if I've ever been to a good conference. My biggest take-homes are ...

Click the button below to download the full transcript of our exclusive interview with TOBI President Michael Khadavi, MD, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

Dr. Steve Sampson, founder of The Orthopedic Institute (TOBI) and the Orthohealing Center, discusses the evolution of orthobiologics, highlighting the integration of machine-based therapies like shockwave and a focus on patient safety, with patients traveling overseas for untested biologic treatments. 

In this interview with SmartTRAK, TOBI founder Steve Sampson, DO, discusses the development of orthobiologics, highlighting a key inflection point where technologies like shockwave and light therapy are used to boost the body's natural healing process. Dr. Sampson also mentions patients traveling abroad for treatments. He warns about the lack of regulatory oversight, potential complications and offers solutions through the Orthohealing Alliance.

Click on the following video (11:10 min) to learn more. A link to download a complete transcript of the interview is provided below.

SmartTRAK: My name is David Shepard. I'm with SmartTRAK, and I'm here at the 16th annual TOBI meeting. and it's my pleasure to be joined by Dr. Steve Sampson. Thanks so much for taking the time. I really appreciate it.

Steve Sampson, DO: Thanks for having me. Looking forward to chatting.

Absolutely. So, the agenda of this year's conference is... It's got a wide range of topics. What do you think is reflected in this year's agenda that really typifies the technologies that are happening out there in the field today?

SS: It's probably the most exciting time in my 20-year career that I feel like we're at this inflection point with new technologies, including machine-based therapies. So, the concept is the human body is remarkable, and we're made of 37 trillion cells, and we have our own drug store, our own ability to self-repair. Our role as physicians is to try to facilitate that. So, machine-based treatments are a big point of this conference where there's a session on shockwave therapy, photo-biomodulation light therapy, hyperbaric oxygen. They're all different machine-based treatments that are trying to boost our body's healing capacity. Then I also have a new session of mesenchymal stem cells or MSCs overseas.

SS: A lot of times, in clinic, we find patients are going to Mexico, Panama, Thailand, and some of them have unlimited resources, but they may not be getting the best level of care and bigger isn't always better.

Right.

SS: So, understanding what are some of the regulatory challenges here in the United States, why are patients going overseas ,,,

Click the button to get the full transcript of our exclusive interview with TOBI founder Steve Sampson, DO, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

In an interview with SmartTRAK, TendoNova's National Sales Director, Ben Browne, discusses the TendoNova device, a minimally invasive percutaneous tool for treating refractory tendinopathy.

In this SmartTRAK interview, National Director of Sales Ben Browne shares his insights on the TendoNova device, a minimally invasive tool for treating refractory tendinopathy through soft tissue fragmentation and debridement that can also be combined with orthobiologics like platelet-rich plasma (PRP). Click on the following video to learn more (08:37 min). A link to download a transcript of the complete interview is also provided below.

James Voos, MD, chair of the Department of Orthopedics and Sports Medicine at University Hospitals Cleveland Medical Center, Cleveland Browns team physician, and president of the NFL Physicians Society (NFLPS), shares his goals for the society and offers insight into how he is using biotechnology to monitor recovery, prevent further injuries, and safely return athletes to competition.

James Voos, MD, president of the NFL Physicians Society (NFLPS), discusses the society's efforts to standardize care for NFL players across the league in an interview with SmartTRAK at the American Orthopaedic Society for Sports Medicine (AOSSM) 2025 Annual Meeting recently held in Nashville, TN.

Dr. Voos also shares an update on ongoing clinical research for osteoarthritis treatment with stem cells. To listen to the interview, please click on the following video (4:18 minutes). A link to download a complete transcript of the interview is alsoprovided below. 

SmartTRAK: Hi, this is Dave Shepard. I'm here at the AOSSM 2025. Keep watching for my interview with Dr. James Voos, who is the team physician for the Cleveland Browns, and also the president of the NFL Physicians’ Society. Dr. Voos, thanks for joining us.

James Voos, MD: Thank you very much for the invitation. I appreciate it.

Excellent. Tell me a little bit about the NFL PS and a little bit about what you're doing, what your initiatives are, what your goals are.

JV: As president of the NFL Physician Society, we represent all of the physicians that provide care for our professional athletes in football. That's not only our orthopedic surgeons, but our medical physicians and all of our associated consultants. So we help to provide standards for how to practice across the league, and that way we assure that every athlete and every team has ...

Interested in how biotechnology can be used to monitor recovery, prevent further injuries and safely return athletes to competition? Click
the button below to download the full transcript of SmartTRAK GM/Sr Analyst David Shepard's interview of James Voos, MD, president of the NFL Physicians Society (NFLPS) from AOSSM 2025.

SmartTRAK provides insights into the latest trends, research and consensus opinions in surgical Orthobiologic treatments and non-operative regenerative medicine from this year’s BA Summit and AANA meetings.